Simon C. Lowry - 03 Mar 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
SVP, R&D, CMO
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 21:21:35 UTC
Previous filing
16 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lowry Simon C SVP, R&D, CMO 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl, Attorney-in-fact 05 Mar 2026 0002044279

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Tax liability -10,636 -12% $8.44* 77,803 05 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Option (Right to buy) Award +44,834 +44% $0.000000* 147,833 03 Mar 2026 Common Stock 44,834 $8.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.